Stephens initiated coverage on C4 Therapeutics with a new price target
$CCCC
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Stephens initiated coverage of C4 Therapeutics with a rating of Equal-Weight and set a new price target of $4.00